Shiseido Liyuan Cosmetics will go to an investor consortium led by IDG Capital.
Shiseido Co. Ltd. is selling its Chinese subsidiary that produces Aupres cosmetics to a consortium of investors led by IDG Capital.
Equity interest in the consolidated subsidiary, Shiseido Liyuan Cosmetics Co. Ltd., or SLC, will be transferred to the consortium, which includes two special purpose vehicles founded by funds managed by IDG and an external management partnership.
“China is a strategically important market for Shiseido and an attractive, dynamic market where the competitive landscape continues to evolve amid the rapid expansion of e-commerce, changing consumer behavior and the emergence of diverse market participants,” the group said in a statement. “Shiseido views these changes as opportunities for growth and seeks to drive sustainable growth and strengthen its competitiveness in China by focusing management resources on areas where it enjoys the greatest competitive advantage.”
SLC was founded in 1991 as a joint venture between Shiseido and Beijing Liyan Co. Ltd., a subsidiary of Yiquing Group, which was owned by the Beijing Municipal Government.
Starting in 1994, SLC manufactured and marketed Aupres skin care, which is sold in China.
By the end of 2025, SLC’s capital was 94 million renminbi, or $14.1 million.
Shiseido’s and Beijing Liyan’s joint venture agreement was expiring in December 2026. In the run-up, Shiseido acquired the 35 percent equity interest in SLC held by Beijing Liyan.
“To achieve sustainable growth for SLC, continued investment in product innovation and digital capabilities is essential in light of evolving market and competitive dynamics,” Shiseido said.
Source link







